You are here

FDA Approves New Use for Bevacizumab (Avastin) in Metastatic Colorectal Cancer

Drug can be continued as second-line treatment after failure of first-line therapy (Jan. 24)

The FDA has approved a new use for bevacizumab (Avastin, Roche) in combination with fluoropyrimidine-based irinotecan or oxaliplatin chemotherapy for patients with metastatic colorectal cancer (mCRC). The new indication will allow patients who received bevacizumab plus irinotecan- or oxaliplatin-containing chemotherapy as first-line treatment for mCRC to continue to receive the drug plus a different irinotecan- or oxaliplatin-containing chemotherapy (second-line treatment) after their cancer worsens.

The approval is based on positive results from the phase III ML18147 study, which showed that patients who continued to receive a bevacizumab-based regimen after their cancer worsened lived longer than patients who switched to chemotherapy alone. The risk of death was reduced by 19% in patients who received bevacizumab in combination with standard chemotherapy as both first- and second-line treatment compared with those who received chemotherapy (hazard ratio [HR] = 0.81; P = 0.0057). The median overall survival was 11.2 months for the bevacizumab group versus 9.8 months for the chemotherapy group. The risk of the cancer worsening or death (progression-free survival) was reduced by 32% in the bevacizumab group (HR = 0.68; P

Avastin (bevacizumab) is the only biologic medicine approved by the FDA as initial treatment for patients with mCRC in combination with intravenous fluorouracil (5FU)-based chemotherapy; as a treatment for patients whose cancer has worsened after chemotherapy alone; and now as a treatment for patients whose cancer has worsened after initial therapy with a bevacizumab-based regimen. Bevacizumab is not indicated for adjuvant treatment of colon cancer.

An independent blood supply is critical for a tumor to grow beyond a certain size (2 mm) and for metastasis to occur. Tumors develop their own blood supply (angiogenesis) by releasing vascular endothelial growth factor (VEGF) — a key driver of tumor growth. Bevacizumab is an antibody that targets and inhibits VEGF for tumor control.

Source: Roche; January 24, 2013.

More Headlines

Atezolizumab in Combination with Chemotherapy is the Only First-line Cancer Immunotherapy for ES-SCLC
Pre-clinical Trials Showed Drug Inhibits Fibroblast Activity and Collagen Deposition
PARG Inhibitor Exploits Weakness, Kills Cells
Inexpensive, Wearable Therapy Increases Arm Mobility, Reduces Stiffness
FDA Prioritizing Review of ARB Applications to Help Mitigate Drug Shortage
California Woman Claimed Asbestos in Talc-Based Powder Caused Her Mesothelioma
Synergistic Effects Seen When Combined With Cisplatin in Mice
National Statistics Report Factors In Race, Ethnicity for the First Time
For Locally Advanced or Metastatic Triple-Negative Type Only